"instanceType","uuid:ID","name","id","description","label","rationale"
"StudyDesign","736c532d-d273-4d8b-8601-7df56b505297","Study Design 1","StudyDesign_1","The main design for the study","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
